[1] |
LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong.
Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978.
|
[2] |
FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua.
Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
|
[3] |
ZHANG Zhaowei, LI Zuojun, HUANG Jian, LI Shuangqing, HE YiLin.
Exploring the outbreak point for clinical pharmacists to provide pharmaceutical care in nephrology department
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 184-188.
|
[4] |
WANG Dan, YAN Xiaoli, ZHANG Yuan.
Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
|
[5] |
ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun.
PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
|
[6] |
DING Jiamin, WANG Youdi, ZHAO Xiali, JIANG Genfeng, CHEN Siwen, HONG Chengcheng, LI Shuqin, HU Weihua.
Study on the treatment of thin endometrium with growth hormone and vitamin E
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 857-862.
|
[7] |
SUI Yuxia, ZHUANG Jie, ZHUANG Min, HUANG Gui.
Delicaflavone inhibits the invasion and migration of gefitinib-resistant lung cancer PC-9/GR cells by regulating epithelial-mesenchymal transition via PI3K/Akt/mTOR pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 614-621.
|
[8] |
WANG Xinli, XU Xiaqing, FANG Hanbing, GUO Yuzhong.
Study of TPA on enhancing the anti-tumor effects of cisplatin and reducing its renal toxicity
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 535-543.
|
[9] |
SHI Jingbin, XIONG Yang.
Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
|
[10] |
YE Xiaodi, MIAO Yunping, CHEN Aiying, CHENG Min, TIAN Xuejun, ZHENG Gaoli .
Optimization and verification of orthotopic non-muscle invasive bladder cancer model in nude mice
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 473-480.
|
[11] |
LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui.
circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
|
[12] |
LEI Jing, HE Ping, CAI Wenlin, ZHANG Yongzhe, ZHANG Beiru, LIU Dajun.
Cordyceps sinensis extracts attenuates HBx-induced mesangial cell proliferation and extracellular matrix synthesis by suppression of the PI3K/Akt pathways
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1247-1254.
|
[13] |
LIU Le, QI Wenbo, BAI Yuping, LIU Qian, YIN Zhenyu, LI Xiaomei, YU Yang, CHEN Hao.
Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 95-101.
|
[14] |
HE Jiaqi, LI Juanjuan, LV Xiaoai, ZHANG Huanhuan, YU Chenhuan.
Reversal effects and mechanisms of Flavonoids from Tetrastigma hemsleyanum on drug resistance in gefitinib-resistant lung cancer cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 368-375.
|
[15] |
JIANG Yuhua, ZHI Hui, LU Linming, TIAN Dahao, WANG Xiaoqing, GE Yu, XIE Shangfu, WANG Qi.
AHVAC-I reverses tumor growth of cancer-associated fibroblasats in gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 389-394.
|